{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ruxolitinib&page=7",
    "query": {
      "intervention": "Ruxolitinib",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 291,
    "total_pages": 30,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ruxolitinib&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ruxolitinib&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T00:46:55.022Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05127421",
      "title": "Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib cream",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "12 Years to 70 Years"
      },
      "enrollment_count": 77,
      "start_date": "2021-11-10",
      "completion_date": "2023-09-29",
      "has_results": true,
      "last_update_posted_date": "2024-08-15",
      "last_synced_at": "2026-10-17T00:46:55.022Z",
      "location_count": 1,
      "location_summary": "Culver City, California",
      "locations": [
        {
          "city": "Culver City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05127421"
    },
    {
      "nct_id": "NCT03954236",
      "title": "Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-sclerotic Cutaneous Chronic Graft-versus-host Disease"
      ],
      "interventions": [
        {
          "name": "topical ruxolitinib 1.5% cream",
          "type": "DRUG"
        },
        {
          "name": "Topical vehicle/moisturizer cream",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2019-05-14",
      "completion_date": "2027-02-06",
      "has_results": true,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-17T00:46:55.022Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03954236"
    },
    {
      "nct_id": "NCT05755438",
      "title": "A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prurigo"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib Cream",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 204,
      "start_date": "2023-03-10",
      "completion_date": "2025-08-13",
      "has_results": true,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-17T00:46:55.022Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Clarkston",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05755438"
    },
    {
      "nct_id": "NCT00778700",
      "title": "A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Placebo Cream",
          "type": "OTHER"
        },
        {
          "name": "Ruxolitinib Phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 199,
      "start_date": "2008-10-28",
      "completion_date": "2009-06-26",
      "has_results": true,
      "last_update_posted_date": "2022-02-09",
      "last_synced_at": "2026-10-17T00:46:55.022Z",
      "location_count": 28,
      "location_summary": "Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 25 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00778700"
    },
    {
      "nct_id": "NCT03920852",
      "title": "A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "12 Years to 65 Years"
      },
      "enrollment_count": 41,
      "start_date": "2019-05-30",
      "completion_date": "2019-12-26",
      "has_results": false,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-10-17T00:46:55.022Z",
      "location_count": 9,
      "location_summary": "Anaheim, California • Encino, California • Miami, Florida + 6 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03920852"
    },
    {
      "nct_id": "NCT07734077",
      "title": "Revumenib in Patients With Myelofibrosis",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis",
        "Post-polycythemia Vera Myelofibrosis",
        "Post-essential Thrombocythemia Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Revumenib",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "FEDRATINIB",
          "type": "DRUG"
        },
        {
          "name": "Momelotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "John Mascarenhas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2026-12-01",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-10-17T00:46:55.022Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07734077"
    },
    {
      "nct_id": "NCT01431209",
      "title": "Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Ruxolitinib Phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2011-08-12",
      "completion_date": "2021-05-26",
      "has_results": true,
      "last_update_posted_date": "2023-10-05",
      "last_synced_at": "2026-10-17T00:46:55.022Z",
      "location_count": 3,
      "location_summary": "Bethesda, Maryland • Rochester, Minnesota • Omaha, Nebraska",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01431209"
    },
    {
      "nct_id": "NCT00726232",
      "title": "Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myeloproliferative Neoplasm (MPN)"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2008-08-20",
      "completion_date": "2018-08-20",
      "has_results": true,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-10-17T00:46:55.022Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00726232"
    },
    {
      "nct_id": "NCT03616184",
      "title": "Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft-versus-host-disease (GVHD)"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2018-09-05",
      "completion_date": "2023-06-12",
      "has_results": true,
      "last_update_posted_date": "2023-10-05",
      "last_synced_at": "2026-10-17T00:46:55.022Z",
      "location_count": 5,
      "location_summary": "Tampa, Florida • Omaha, Nebraska • Cleveland, Ohio + 2 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03616184"
    },
    {
      "nct_id": "NCT04817007",
      "title": "A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "BMS-986158",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Fedratinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 216,
      "start_date": "2021-03-22",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-10-17T00:46:55.022Z",
      "location_count": 8,
      "location_summary": "Newport Beach, California • Lake Mary, Florida • New Orleans, Louisiana + 5 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04817007"
    }
  ]
}